Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc is currently advancing its clinical-stage programs, with positive interim results from the Phase 3 trials for tinlarebant in treating STGD1, which may enhance investor interest due to the drug's potential impact on untreated eye diseases. The company is experiencing increased investor attention, driven by updates from its ongoing trials, and it has strategically increased the sample size for the ongoing PHOENIX trial, reflecting confidence in recruitment and study framework. Furthermore, Belite Bio has secured additional funding avenues while achieving several designations, including fast track and orphan drug status, which could streamline the regulatory process and improve market positioning for its innovative therapeutics.

Bears say

Belite Bio Inc has consistently reported operating losses since its inception, with a net loss of $36.1 million in 2024, suggesting a prolonged path to potential profitability. Uncertainties surrounding healthcare spending, reimbursement policies, and regulatory risks could adversely affect the company's revenue streams and increase operational costs, thereby heightening the financial risk associated with the stock. Additionally, fluctuations in consumer spending due to economic conditions may further impede patient access to necessary treatments, adding layers of volatility to Belite Bio's financial outlook.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.